FindTrial
Sign In

Blood Test Levels to Detect Joint Disease Early and Predict How Serious It May Become

Evaluation of PTX-3 as a novel marker for diagnosis & prognosis of RA. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111480
Enrollment
31
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Datta Meghe Institute of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with rheumatoid arthritis who meet ACR/EULAR criteria. 2. At least eighteen years old. 3. Patients who are prepared to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Individuals who have either acute or persistent infections. 2. Individuals suffering from various autoimmune conditions. 3. Individuals suffering from malignancy, chronic liver disease,or kidney illness. 4. Women who are lactating or pregnant. 5. Individuals receiving long-term steroid treatment for illnesses other than RA.

Design outcomes

Primary

MeasureTime frame
When comparing RA patients to controls, pentraxin-3 levels should be noticeably higher.Timepoint: A weekly in once , total time duration Assessment will be done at 2 year—

Secondary

MeasureTime frame
Compared to CRP & ESR, PTX-3 is expected to exhibit a greater correlation with disease activity.Timepoint: A weekly in once , total time duration Assessment will be done at 2 year—

Countries

India

Contacts

Public ContactDr Meghali Kaple

Datta Meghe Institute of Higher Education and Research

drmegham@rediffmail.com9527863610

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026